Life Time Group Holdings Inc. Common Stock vs Novavax Inc — how do they compare? Life Time Group Holdings Inc. Common Stock trades at $40.62 (market cap $9.00B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Life Time Group Holdings Inc. Common Stock is far larger — about 4.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Life Time Group Holdings Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Life Time Group Holdings Inc. Common Stock for 1 Days and Novavax Inc for 59 Days on average.
| LTH | NVAX | |
|---|---|---|
Market Cap | $9.00B | $1.82B |
Volume | 2,696,923 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $45.73 | $12.75 |
52-Week Low | $24.59 | $6.22 |
Typical Hold Time | 1 Days | 59 Days |
Enterprise Value | $13.05B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →